Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nifedipine

FDA-approved product (capsule, oral), marketed as Adalat, Adalat Cc, Afeditab Cr and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Nifedipine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Coronary Vasospasm
  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dihydropyridine derivatives
FDA pharmacologic class
Dihydropyridine Calcium Channel Blocker FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nifedipine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nifedipine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

    NCT07746271 · start 2026-09-30

    Registered record
    Registry ID
    NCT07746271
    Conditions
    Hypertension in Pregnancy; Obstetrical Complications
    Interventions
    Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg; Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-09-30
    Completion
    2030-04-30
    Enrolment
    4,120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension in Pregnancy; Obstetrical Complications
    InterventionAnti-hypertensive medication titrated to a BP goal of <140/90 mmHg; Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHg
    PhasePhase 3
    Registry statusNot yet recruiting

  • Topical Nifedipine 0.3% Plus Lidocaine 1.5% for Uncomplicated Hemorrhoidal Disease

    NCT07295886 · start 2025-09-02

    Registered record
    Registry ID
    NCT07295886
    Conditions
    Hemorrhoid Bleeding; Hemorrhoids Prolapse; Hemorrhoid Pain; Hemorrhoid; Topical Administration
    Interventions
    topical nifedipine 0.3% plus lidocaine 1.5%
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-09-02
    Completion
    2026-05-02
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemorrhoid Bleeding; Hemorrhoids Prolapse; Hemorrhoid Pain; Hemorrhoid +1 more
    Interventiontopical nifedipine 0.3% plus lidocaine 1.5%
    PhaseNot recorded
    Registry statusRecruiting

  • Postpartum Evaluation of Nifedipine and Enalapril for Hypertension

    NCT07023003 · start 2025-07-11

    Registered record
    Registry ID
    NCT07023003
    Conditions
    Hypertension in Pregnancy
    Interventions
    Enalapril 10mg QD; Nifedipine 30mg XL BID
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-07-11
    Completion
    2028-12
    Enrolment
    850

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension in Pregnancy
    InterventionEnalapril 10mg QD; Nifedipine 30mg XL BID
    PhasePhase 4
    Registry statusRecruiting

  • Comparison in Cervical Length and Prolongation of Gestation Age on Vaginal Progesterone Administration to Pregnant Women After the Acute Phase of Threatened Preterm Birth

    NCT06975943 · start 2025-01-01

    Registered record
    Registry ID
    NCT06975943
    Conditions
    Pregnant Women; Pregnancies at Increased Risk of Preterm Birth
    Interventions
    Progesterone 200 mg vaginal capsules
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-01-01
    Completion
    2026-02-28
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnant Women; Pregnancies at Increased Risk of Preterm Birth
    InterventionProgesterone 200 mg vaginal capsules
    PhaseNot applicable
    Registry statusCompleted

  • Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia

    NCT06220721 · start 2024-10-23

    Registered record
    Registry ID
    NCT06220721
    Conditions
    Hypertension, Pregnancy-Induced
    Interventions
    Nifedipine ER
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-10-23
    Completion
    2029-06-30
    Enrolment
    618

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pregnancy-Induced
    InterventionNifedipine ER
    PhaseNot applicable
    Registry statusRecruiting

  • Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy

    NCT06501651 · start 2024-08-01

    Registered record
    Registry ID
    NCT06501651
    Conditions
    Essential Hypertension; Type 2 Diabetes; Nephropathy
    Interventions
    Sacubitril/Valsartan; Valsartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2024-08-01
    Completion
    2025-04-10
    Enrolment
    297

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension; Type 2 Diabetes; Nephropathy
    InterventionSacubitril/Valsartan; Valsartan
    PhasePhase 4
    Registry statusUnknown

  • Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine

    NCT06265415 · start 2024-03-30

    Registered record
    Registry ID
    NCT06265415
    Conditions
    Severe Preeclampsia
    Interventions
    Labetalol; Nitroglycerine; Nifedipine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2024-03-30
    Completion
    2025-03-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Preeclampsia
    InterventionLabetalol; Nitroglycerine; Nifedipine
    PhaseNot applicable
    Registry statusUnknown

  • Cerebral Autoregulation Guiding Blood Pressure Management After Revascularization

    NCT05670028 · start 2023-06-04

    Registered record
    Registry ID
    NCT05670028
    Conditions
    Ischemic Stroke; Revascularization; Blood Pressure; Cerebrovascular Insufficiency; Cerebral Autoregulation; Individuation; Hemorrhagic Transformation Due to Acute Stroke
    Interventions
    Hypotensive Drugs and/or Vasoactive Drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-06-04
    Completion
    2026-06-04
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke; Revascularization; Blood Pressure; Cerebrovascular Insufficiency +3 more
    InterventionHypotensive Drugs and/or Vasoactive Drugs
    PhasePhase 2
    Registry statusUnknown

  • Nifedipine Versus Magnesium Sulfate for Late Preterm Tocolysis

    NCT05343806 · start 2023-04-13

    Registered record
    Registry ID
    NCT05343806
    Conditions
    Threatened Preterm Labor
    Interventions
    Nifedipine 20 Mg; Magnesium Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-04-13
    Completion
    2025-09-01
    Enrolment
    264

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThreatened Preterm Labor
    InterventionNifedipine 20 Mg; Magnesium Sulfate
    PhaseNot applicable
    Registry statusCompleted

  • The Treatment of Magnesium Sulfate and Nifedipine in Preterm Labor Threat

    NCT05520021 · start 2022-09-01

    Registered record
    Registry ID
    NCT05520021
    Conditions
    Preterm Labor Without Delivery; Pregnancy Preterm
    Interventions
    Nifedipine; Magnesium sulfate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-09-01
    Completion
    2023-03-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreterm Labor Without Delivery; Pregnancy Preterm
    InterventionNifedipine; Magnesium sulfate
    PhaseNot applicable
    Registry statusUnknown

  • Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

    NCT05309460 · start 2022-06-20

    Registered record
    Registry ID
    NCT05309460
    Conditions
    Postpartum Preeclampsia; Hypertension in Pregnancy
    Interventions
    Labetalol Oral Tablet; NIFEdipine ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-06-20
    Completion
    2024-12-01
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostpartum Preeclampsia; Hypertension in Pregnancy
    InterventionLabetalol Oral Tablet; NIFEdipine ER
    PhasePhase 4
    Registry statusRecruiting

  • Efficacy of Polyethylene Glycol vs Lactulose With Isabgol in Acute Fissure-in-Ano: PEGASIS Trial

    NCT05341180 · start 2022-05-27

    Registered record
    Registry ID
    NCT05341180
    Conditions
    Anal Fissure; Constipation
    Interventions
    Polyethylene Glycol; Isabgol + Lactulose
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2022-05-27
    Completion
    2023-07-22
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnal Fissure; Constipation
    InterventionPolyethylene Glycol; Isabgol + Lactulose
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • The Efficacy of Nifedipine in the Management of Preterm Labor

    NCT04644354 · start 2020-12-15

    Registered record
    Registry ID
    NCT04644354
    Conditions
    Preterm Labor; Preterm Birth; Preterm Labor Without Delivery; Preterm Labor With Preterm Delivery in Third Trimester; Calcium-Channel Blockers Toxicity; Side Effect of Drug
    Interventions
    Nifedipine 10 mg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-12-15
    Completion
    2020-12-30
    Enrolment
    444

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreterm Labor; Preterm Birth; Preterm Labor Without Delivery; Preterm Labor With Preterm Delivery in Third Trimester +2 more
    InterventionNifedipine 10 mg
    PhaseNot recorded
    Registry statusUnknown

  • Bioequivalence of Extended Release Nifedipine Tablets in Healthy Chinese Subjects

    NCT04438720 · start 2020-06-25

    Registered record
    Registry ID
    NCT04438720
    Conditions
    Therapeutic Equivalency
    Interventions
    Extended Release Nifedipine Tablets 30 mg; Extended Release Nifedipine Tablets 30 mg (Adalat® GITS)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2020-06-25
    Completion
    2020-09-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTherapeutic Equivalency
    InterventionExtended Release Nifedipine Tablets 30 mg; Extended Release Nifedipine Tablets 30 mg (Adalat® GITS)
    PhasePhase 1
    Registry statusUnknown

  • Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    NCT04278404 · start 2020-03-05

    Registered record
    Registry ID
    NCT04278404
    Conditions
    Coronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension; Pain; Hyperphosphatemia; Primary Hyperaldosteronism; Edema; Hypokalemia; Heart Failure; Hemophilia; Menorrhagia; Insomnia; Pneumonia; Skin Infection; Arrythmia; Asthma in Children; Bronchopulmonary Dysplasia; Adrenal Insufficiency; Fibrinolysis; Hemorrhage; Attention Deficit Hyperactivity Disorder; Multisystem Inflammatory Syndrome in Children (MIS-C); Kawasaki Disease; Coagulation Disorder; Down Syndrome
    Interventions
    The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-03-05
    Completion
    2026-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus Infection (COVID-19); Pulmonary Arterial Hypertension; Urinary Tract Infections in Children; Hypertension +22 more
    InterventionThe POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
    PhaseNot recorded
    Registry statusRecruiting